# Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine

> **NCT02996773** · PHASE1 · COMPLETED · sponsor: **University of Arizona** · enrollment: 50 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Acute Myelogenous Leukemia
- Myelodysplastic Syndromes
- Chronic Myelogenous Leukemia
- Lymphoma,Non-Hodgkin
- Lymphoma, Hodgkin
- Lymphoma, Follicular
- Marginal Zone Lymphoma
- Large Cell Lymphoma
- Mantle-Cell Lymphoma
- Gray Zone Lymphoma
- Burkitt Lymphoma
- High Risk Undifferentiated Acute Leukemia

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT02996773
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-29
- **Primary completion:** 2025-08-01
- **Final completion:** 2025-08-01
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02996773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02996773, "Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT02996773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*